Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 211

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 211
---
 30, 2025 (unaudited)$— $— $11,448 $11,448 As aforementioned, the remaining liability as of June 30, 2025 for the contingent consideration related to the USWM Acquisition was reclassified to Other Current Liabilities in the second quarter of 2025. Thereafter, the Company made an additional milestone payment of  $1.9 million in the third quarter of 2025. USWM AcquisitionAdamas AcquisitionTotalBalance at December 31, 2023$46,400 $7,050 $53,450 Change in fair value recognized in earnings130 (6,596)(6,466)Balance at September 30, 2024 (unaudited)$46,530 $454 $46,984 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•The Company recorded a $7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the nine months ended September 30, 2025. No expense was recorded during the three months ended September 30, 2025. The Company recorded a $1.3 million expense and a $0.1 million expense due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:•The Company recorded a $2.3 million gain and a $6.6 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three and nine months ended September 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to passage of time. The Company recorded the following changes in the fair value of contingent consideration liability for the Sage CVRs:•The Company recorded a contingent consideration liability of $11.4 million at Sage Closing Date. No change in fair value was recorded during the three and nine months ended September 30, 2025 given the proximity of the Sage Acquisition to